Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Challenging Adult and Pediatric Autoimmune Connective Tissue Disease Cases: Pearls for Diagnosis and Management
Description
This presentation discusses the diagnostic challenges and management strategies for adult and pediatric autoimmune connective tissue diseases, particularly systemic sclerosis. The speaker highlights patient cases with characteristic symptoms such as taut skin, joint contractures, and positive prayer and fist signs indicative of the disease. Early recognition of signs like puffy hand syndrome and conditions such as Raynaud’s can lead to timely interventions. The use of mycophenolate mofetil is emphasized as treatment for skin involvement and related interstitial lung disease. The presentation also addresses the psychosocial impacts of systemic sclerosis, including the burden of skin symptoms like salt and pepper pigmentation and telangiectasias. Treatment options for these symptoms, such as hyaluronidase injections for microstomia and laser treatment for telangiectasias, are discussed, with examples of successful patient outcomes illustrating improvements in quality of life and self-image. The speaker stresses the importance of managing all cutaneous manifestations to enhance patient well-being, advocating for a comprehensive approach to treatment.
View moreConclusions
- Systemic sclerosis is characterized by early signs such as puffy hand syndrome and significant skin changes, including joint contractures and the prayer and fist signs.
- Early diagnosis of systemic sclerosis is crucial for timely intervention, potentially preventing progression to severe outcomes like sclerodactyly.
- Mycophenolate mofetil has been shown to significantly reduce skin involvement and improve joint mobility in patients with systemic sclerosis.
- The use of mycophenolate mofetil is also beneficial for managing systemic manifestations like interstitial lung disease in scleroderma.
- Quality of life in systemic sclerosis patients is markedly lower compared to those with other chronic diseases due to both physical and psychological burdens associated with the disease.
- Treatment strategies addressing skin manifestations, such as salt and pepper dyspigmentation, microstomia, and perioral furrowing, can substantially improve patients' quality of life.
- Psychological impacts of visible symptoms like telangiectasias highlight the need for comprehensive management strategies in systemic sclerosis.
- Aggressive treatment protocols and patient education are vital to improve disease outcomes and enhance life quality for those affected by systemic sclerosis.
- Mendoza, F. A., Nagle, S. J., Lee, J. B., & Jimenez, S. A. (2012). A Prospective Observational Study of Mycophenolate Mofetil Treatment in Progressive Diffuse Cutaneous Systemic Sclerosis of Recent Onset. The Journal of Rheumatology.
- Tashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., ... & for the Sclerodema Lung Study II Investigators. (2016). Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med, 4(9), 708-719.
- Chularojanamontri, L., Sethabutra, P., Kulthanan, K., & Manapajon, A. (2024). Dermatology life quality index in Thai patients with systemic sclerosis: A cross-sectional study.
- Min, M. S., Mazori, D. R., Kassamali, B., Cobos, G., Ho, A., LaChance, A. H., & Vleugels, R. A. (2022). Treatment With Mycophenolate Mofetil for Salt-and-Pepper Dyspigmentation Caused by Autoimmune Sclerosing Disease. JAMA Dermatol, 158(3), 327-329. doi:10.1001/jamadermatol.2021.5848.
- Min, M. S., Goldman, N., Mazori, D. R., Guo, L. N., & Vleugels, R. A. (2023). Hyaluronidase Injections for Oral Microstomia in Systemic Sclerosis and Mixed Connective Tissue Disease. JAMA Dermatol, 159(12), 1393-1395. doi:10.1001/jamadermatol.2023.3893.
- Ennis, H., Herrick, A. L., Cassidy, C., Griffiths, C. E. M., & Richards, H. L. (2013). A pilot study of body image dissatisfaction and the psychological impact of systemic sclerosis-related telangiectases. Clin Exp Rheumatol, 31(2 Suppl 76), 12-7.
- Halachmi, S., Gabari, O., Cohen, S., Koren, R., Ben Amitai, D., & Lapidoth, M. (2014). Telangiectasis in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment. Lasers Med Sci, 29(1), 137-140. doi:10.1007/s10103-013-1298-1.